Diabetes Education Book Publisher

Executive Summary​

​

We're building​ a small wireless device to collect data from blood glucose meters used in the management of diabetes. It replaces the need for patients to have a cell phone and the user experience is seamless. It just works! Finally, every organization who needs access to blood sugar data from their hardest to reach and most costly health plan members will be able to have it. For this team, it's a simple upgrade to the research device we first deployed nearly 15 years ago. To others, it's magic.

​

The following information is intended to share insight as to why a cheaper, faster, better wireless device is needed and how we plan to commercialize it.

​

The Opportunity

​

Commercial information technologies for helping patients better manage chronic diseases like diabetes assume that:

​

• doctors are willing to be at the center of day-to-day outpatient self-care;

​

• every patient has a smart phone with a data plan; and,

 

• every patient is willing to spend more time to share data with their doctor.

​

All of these built-in assumptions fail miserably when compared to the real world.

 

This high-tech data sharing scenario is a reality for fewer than 5% of the doctor and patient relationships. Because of the DiaTrends team's decade of primary research, including hands-on experience working with thousands of patients, we know that the vast majority of people will never use the current generation mobile apps. No wonder health plans refuse to pay for them.

 

The Team

​

The founders behind DiaTrends are informed like no other team due to the research & development that went into the design, build and field testing of the GlucoMON®-ADMS by Diabetech. It's finally time to commercialize the concepts first identified by Diabetech's research program so we've spun out DiaTrends as the vehicle to commercialize that experience. We know that in order to have a significant impact on the masses, passive data collection is an absolute requirement. Only then can you hope to work with patients to change behavior with proven effective methods involving data driven interventions.

 

Diabetech's pioneering research culminated in several peer reviewed journal publications. This evidence base resulted in licensing of the Diabetech technology to medical device and disease management companies in the USA and UK.
 

Barriers​

​

Doctors and other medical professionals do not get paid to review outpatient self-reported data. Patients are far too busy to bother with uploading blood glucose meters and other biometic sensors.

​

Since 2009, when Diabetech first licensed its technology, companies selling data-driven patient management devices and programs have continued to struggle. This is because every company in the space is totally dependent on a scenario built for motivated patients using a smart phone with a data plan. These companies also assume that the patient's doctor is willing to review their patient's blood sugar data and that they will then prescribe timely adjustments to the patient. This belief has proven time and again to exist only as fantasy.

 

In response, these same companies believe that their systems will be more effective and attractive to payers if doctors had access to even more data. Thus, the push for incorporating the patient's photos of meals, accelerometer data from exercise bracelets, location, temperature, blood pressure, pulse oximetry and every other sensor under the Sun. "Combine all of this data in an Artificial Intelligence platform and the problem could be solved", so they want payers and investors to believe. Meanwhile, proven elegant patient self-directed protocols sit idle.

​

The Solution